NO20050445L - Synergistisk interaksjon mellom abacavir og alovudin - Google Patents

Synergistisk interaksjon mellom abacavir og alovudin

Info

Publication number
NO20050445L
NO20050445L NO20050445A NO20050445A NO20050445L NO 20050445 L NO20050445 L NO 20050445L NO 20050445 A NO20050445 A NO 20050445A NO 20050445 A NO20050445 A NO 20050445A NO 20050445 L NO20050445 L NO 20050445L
Authority
NO
Norway
Prior art keywords
alovudine
abacavir
synergistic interaction
treatment
combined
Prior art date
Application number
NO20050445A
Other languages
English (en)
Norwegian (no)
Inventor
Goran Mardh
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202022A external-priority patent/SE0202022D0/xx
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of NO20050445L publication Critical patent/NO20050445L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
NO20050445A 2002-06-27 2005-01-26 Synergistisk interaksjon mellom abacavir og alovudin NO20050445L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0202022A SE0202022D0 (sv) 2002-06-27 2002-06-27 Synergistic interaction of abacavir and alovudine
EP02024744 2002-11-06
PCT/SE2003/001100 WO2004002433A1 (fr) 2002-06-27 2003-06-24 Interaction synergique d'abacavir et d'alovudine

Publications (1)

Publication Number Publication Date
NO20050445L true NO20050445L (no) 2005-01-26

Family

ID=30001852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050445A NO20050445L (no) 2002-06-27 2005-01-26 Synergistisk interaksjon mellom abacavir og alovudin

Country Status (19)

Country Link
US (1) US20060084627A1 (fr)
EP (1) EP1536800B1 (fr)
JP (1) JP2005533870A (fr)
KR (1) KR20050013628A (fr)
CN (1) CN1302779C (fr)
AT (1) ATE314851T1 (fr)
AU (1) AU2003239088B2 (fr)
BR (1) BR0311141A (fr)
CA (1) CA2481890A1 (fr)
DE (1) DE60303131T2 (fr)
ES (1) ES2254941T3 (fr)
HK (1) HK1079981B (fr)
IL (1) IL164921A0 (fr)
MX (1) MXPA04012754A (fr)
NO (1) NO20050445L (fr)
NZ (1) NZ535817A (fr)
PL (1) PL373758A1 (fr)
RU (1) RU2320347C2 (fr)
WO (1) WO2004002433A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087169A1 (fr) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Combinaison antivirale de nevirapine et d'un autre compose antiretroviral
GB0608876D0 (en) 2006-05-05 2006-06-14 Medivir Ab Combination therapy
KR20170078868A (ko) * 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
GB8719877D0 (en) * 1987-08-22 1987-09-30 Wellcome Found Antiviral compounds
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
MXPA01001507A (es) * 1998-08-10 2003-09-10 Novirio Pharmaceuticals Ltd °l-2'desoxi-nucleosidos para el tratamiento de hepatitis b.
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
CN101219148A (zh) * 1999-01-22 2008-07-16 爱莫里大学 由β-2’,3’-二脱氢-2’,3’-二脱氧-5-氟胞苷选择的HIV-1突变
US6514979B1 (en) * 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
NZ523123A (en) * 2000-06-02 2005-12-23 Smithkline Beecham Corp Methods of treating viral diseases with IL-18 and IL-18 combinations with anti-viral drugs

Also Published As

Publication number Publication date
WO2004002433A8 (fr) 2004-05-06
BR0311141A (pt) 2005-06-07
DE60303131D1 (de) 2006-03-30
HK1079981A1 (en) 2006-04-21
JP2005533870A (ja) 2005-11-10
EP1536800A1 (fr) 2005-06-08
RU2005101874A (ru) 2005-06-27
MXPA04012754A (es) 2005-03-23
NZ535817A (en) 2006-11-30
DE60303131T2 (de) 2006-07-20
CA2481890A1 (fr) 2004-01-08
IL164921A0 (en) 2005-12-18
HK1079981B (zh) 2007-10-12
RU2320347C2 (ru) 2008-03-27
CN1665509A (zh) 2005-09-07
ATE314851T1 (de) 2006-02-15
CN1302779C (zh) 2007-03-07
ES2254941T3 (es) 2006-06-16
PL373758A1 (en) 2005-09-05
AU2003239088B2 (en) 2006-11-02
KR20050013628A (ko) 2005-02-04
EP1536800B1 (fr) 2006-01-04
WO2004002433A1 (fr) 2004-01-08
US20060084627A1 (en) 2006-04-20
AU2003239088A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
MXPA03007712A (es) Sales farmaceuticas.
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
AR032293A1 (es) Estuche farmaceutico
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
HK1068606A1 (en) Novel aminobenzoephenones
GB0002336D0 (en) Medicaments
ATE291908T1 (de) Ibuprofen-wirkstoffzubereitung
PL366800A1 (en) Tablet comprising cetirizine and pseudoephedrine
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
NO20050445L (no) Synergistisk interaksjon mellom abacavir og alovudin
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
HUP0204208A2 (hu) Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény
EP1273301A3 (fr) Préparations pharmaceutiques comprenant des principes actifs susceptibles d'administration illicite
AU2003281468A1 (en) P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient
AU2002256775A1 (en) Therapeutic method for inducing tolerance
ATE261732T1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
AU2002225097A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
ATE361097T1 (de) Orale vakzinierung mit dem tumor-antigen-mimotop gln-met-trp-ala-pro-gln-trp-gly-pro-asp
SE0000332D0 (sv) New use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application